Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dabomb Protein BiotechROCO:6578 -1.92%57 Interest Coverage is 2.88 as of Mar. 2026, which is 84% below its 10-year median of 18.49. GuruFocus rates ROCO:6578 with a GF Score™ of 57/100 and a GF Value™ of NT$16.49 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,517 Consumer Packaged Goods companies, Dabomb Protein Biotech ranks worse than 65919.51% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Dabomb Protein Biotech's
Operating Income
for the
three
months ended in Mar. 2026 was NT$0.7 Mil. Dabomb Protein Biotech's Interest Expense for the
three
months ended in Mar. 2026 was NT$-0.3 Mil.
Dabomb Protein Biotech's interest coverage for the quarter that ended in Mar. 2026 was 2.88.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Dabomb Protein Biotech's Interest Coverage or its related term are showing as below:
ROCO:6578's Interest Coverage is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 8.43 * Ranked among companies with meaningful Interest Coverage only.
Dabomb Protein Biotech (ROCO:6578) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Dabomb Protein Biotech Interest Coverage Related Terms
Dabomb Protein Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Dabomb Protein Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:6578 vs KHC, GIS: Interest Coverage Comparison
For the Packaged Foods subindustry, Dabomb Protein Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech Interest Coverage vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's Interest Coverage falls into.
Dabomb Protein Biotech Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a Interest Coverage of 2.88 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Dabomb Protein Biotech and its competitors. This is 84% below median its historical median of 18.49. According to the industry distribution chart, Dabomb Protein Biotech ranks #999999 out of 1517 companies in the Consumer Packaged Goods industry.
Is Dabomb Protein Biotech's Interest Coverage too high?
Dabomb Protein Biotech's current Interest Coverage of 2.88 is 84% below median its 10-year median of 18.49. The Consumer Packaged Goods industry median Interest Coverage is 8.43. Dabomb Protein Biotech's value of 2.88 is 65.8% below this industry median. Based on the distribution chart, Dabomb Protein Biotech ranks #999999 out of 1517 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Dabomb Protein Biotech has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Interest Coverage compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #999999 out of 1517 companies for Interest Coverage. This places Dabomb Protein Biotech in the lower half of its industry. The industry median Interest Coverage is 8.43. Dabomb Protein Biotech's value of 2.88 is 65.8% below this benchmark. While the company's 10-year median is 18.49 vs. the industry median of 8.43, Dabomb Protein Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Consumer Packaged Goods company?
The median Interest Coverage among Consumer Packaged Goods companies is 8.43, based on 1,517 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dabomb Protein Biotech's current Interest Coverage of 2.88 is 65.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Dabomb Protein Biotech and its competitors. For the Consumer Packaged Goods industry, the median Interest Coverage is 8.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current Interest Coverage is 2.88, which is 84% below median its own 10-year median of 18.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Fairly Valued. The stock's GF Value™ is NT$16.49, compared to a current price of NT$17.90 — trading 8.6% above its estimated fair value. The current Interest Coverage is 2.88, which is 84% below median its 10-year median of 18.49 and 65.8% below the Consumer Packaged Goods industry median of 8.43. Dabomb Protein Biotech's overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Interest Coverage is 2.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued.
The current stock price of NT$17.90 is trading 8.6% above its estimated GF Value™ of NT$16.49.
GuruFocus considers Dabomb Protein Biotech to be Fairly Valued.
Key valuation signals for ROCO:6578:
Interest Coverage: 2.88 (84% below median its 10-year median of 18.49)
GF Value™: NT$16.49 vs. price of NT$17.90 (8.6% above fair value)
Industry Position: 65.8% below the Consumer Packaged Goods median (#999999 of 1517)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
57GF Score
Get the complete analysis for ROCO:6578
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
